Absorbable Vascular Filter
Adient Medical is leading the development of an absorbable vascular filter for the prevention of pulmonary embolism (PE), a leading cause of death in the US claiming the lives of over 100,000 Americans annually — more than breast cancer, AIDS, and traffic fatalities combined.
“Few complications in medicine and surgery are as unpredictable, treacherous and dramatically tragic as the thromboembolic phenomena” (Michael DeBakey, Journal of the American Medical Association, 1943;123,(12)).
Adient has successfully completed a First in Human study and is advancing a randomized controlled study in the US.
“In the postoperative patient, asymptomatic [fatal] PE occurred 4 times as often as did symptomatic PE.” Mayo Clinic.
Unfortunately today, PE remains a persistent problem with little warning as over half of the fatal pulmonary emboli occur without symptom. The Adient absorbable inferior vena cava (IVC) filter is inserted via catheter and serves to capture blood clots traveling to the lungs for 12 weeks for at risk patients, then vanishes following the dissolution of acute blood clots, into mere carbon dioxide and water. Consequently, the impact of the absorbable filter on patient care will be significant as it is expected to:
- Save lives by preventing pulmonary embolism,
- Save costs by eliminating expensive filter retrieval procedures,
- Provide a safer alternative since the filter is incapable of perforating the IVC and impaling neighboring organs as experienced with conventional IVC metal filters.